H. Lundbeck

H. Lundbeck (CPH:LUN) Sales of Cipralex® and Azilect® were up by 21% and 42%, respectively, at constant exchange rates in Q3 2008, and Ebixa® sales rose by 12% in Q3 2008 compared with the year-earlier period. Revenue growth was driven by increases in the markets in Europe and in International Markets, with both segments recording growth of 12% at constant exchange rates in Q3 2008 relative to Q3 2007.

H. Lundbeck (CPH:LUN) H. Lundbeck A/S announced today that the U.S. Food and Drug Administration (FDA) has completed the initial check for completeness and accepted the New Drug Application on Serdolect® for the treatment of schizophrenia for review. This is the first NDA submitted in the US by Lundbeck, and it follows the launch of Serdolect® in Europe, South and Central America, Asia, and the Middle East.

H. Lundbeck (CPH:LUN) Lundbeck's partner Teva Pharmaceutical Industries Ltd. has announced today that results of the phase III ADAGIO trial were presented during the 12th Congress of European Federation of Neurological Societies (EFNS) in Madrid, Spain. The ADAGIO study showed that Parkinson's disease patients who took Azilect® (rasagiline) 1mg tablets once-daily upon entry into the trial, demonstrated a significant improvement compared to those who initiated therapy with the drug nine months later. The 1mg dose met all three primary endpoints, as well as the secondary endpoint, with statistical significance.

H. Lundbeck (CPH:LUN) H. Lundbeck A/S hereby reports transactions made by executives and persons and legal entities closely associated to them with shares in H. Lundbeck A/S and linked securities, cf. section 28a of the Danish Securities Trading Act.

H. Lundbeck (CPH:LUN) Lundbeck achieved an exceptionally strong financial performance in Q2 2008 with revenue continuing to grow and climbing 12% on the year-earlier period. Exclusive of a DKK 481 million writedown of the value of the Flurizan® rights, profit from operations rose 22% relative to the same period of last year. Lundbeck retains its financial guidance for 2008, which now includes a reduction of escitalopram inventories to Lundbeck's US partner Forest Laboratories, Inc. during H2 2008.

H. Lundbeck On 31 July 2008, H. Lundbeck A/S was notified that LFI A/S (the Lundbeck Foundation) after today's registered change of the H. Lundbeck A/S' share capital holds 69.7621% of the shares in Lundbeck corresponding to 137,351,918 shares.

H. Lundbeck On 22 April 2008, the Annual General Meeting of H. Lundbeck A/S resolved to reduce the company's share capital by a nominal amount of DKK 51,966,745 by reducing the company's holding of treasury shares.

H. Lundbeck On 22 April 2008, the Annual General Meeting of H. Lundbeck A/S resolved to reduce the company's share capital by a nominal amount of DKK 51,966,745 by reducing the company's holding of treasury shares.

H. Lundbeck Myriad Genetics, Inc. has today announced the outcome of a clinical phase III trial of Flurizan® (tarenflurbil) in 1,684 patients with mild Alzheimer's disease. The clinical phase III data do not correspond to the data observed in clinical phase II in patients with mild Alzheimer's disease. Lundbeck and Myriad will now investigate the data further to understand the outcome of the trial in which the compound did not meet the two primary endpoints.

H. Lundbeck Lundbeck's partner Teva Pharmaceutical Industries Ltd. has today announced the successful completion of ADAGIO, the phase III trial designed to demonstrate that Azilect® 1 mg tablets can slow down the progression of Parkinson's disease. In the trial, the currently marketed Azilect® 1 mg tablets met all three primary end points, as well as the secondary and additional end points, all with statistical significance. The study also confirmed the safety and tolerability of Azilect®.